Akorn, Inc. and Cipla, Ltd., a pharmaceutical company located in Mumbai, India, have signed an exclusive development and supply agreement for an oral ANDA drug product for the prevention of organ transplant rejection. Under the terms of the 10-year agreement, Cipla will be responsible for the development, manufacturing and supply of the drug product. Akorn will be responsible for the bioequivalency clinical trial, ANDA submission and marketing and distribution in the U.S. and PR. Cipla will...